Wall Street Zen downgraded shares of Turn Therapeutics (NASDAQ:TTRX – Free Report) from a hold rating to a sell rating in a research report sent to investors on Sunday,Wall Street Zen reports.
Other research analysts also recently issued research reports about the stock. Weiss Ratings downgraded shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. WBB Securities raised shares of Turn Therapeutics from a “sell” rating to a “hold” rating and set a $10.00 target price for the company in a research report on Friday, October 23rd. LADENBURG THALM/SH SH upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Lucid Cap Mkts raised shares of Turn Therapeutics to a “strong-buy” rating in a report on Thursday, September 24th. Finally, Zacks Research raised Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.00.
View Our Latest Analysis on TTRX
Turn Therapeutics Stock Performance
Shares of NASDAQ TTRX opened at $9.92 on Friday. Turn Therapeutics has a 12-month low of $2.57 and a 12-month high of $16.45. The stock’s fifty day simple moving average is $11.71 and its two-hundred day simple moving average is $7.18. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 8.83.
Turn Therapeutics (NASDAQ:TTRX – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.21) earnings per share for the quarter. Equities analysts expect that Turn Therapeutics will post -0.40 EPS for the current year.
Hedge Funds Weigh In On Turn Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. SteelPeak Wealth LLC grew its position in Turn Therapeutics by 0.7% during the 3rd quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company’s stock worth $3,616,000 after purchasing an additional 1,819 shares during the last quarter. Ieq Capital LLC purchased a new position in shares of Turn Therapeutics in the second quarter worth $1,660,000. BlackRock Inc. acquired a new stake in shares of Turn Therapeutics during the second quarter worth $282,000. Bridgewater Advisors Inc. acquired a new stake in shares of Turn Therapeutics during the second quarter worth $242,000. Finally, HighTower Advisors LLC grew its holdings in shares of Turn Therapeutics by 23.3% during the third quarter. HighTower Advisors LLC now owns 24,279 shares of the company’s stock valued at $349,000 after buying an additional 4,595 shares during the last quarter.
Turn Therapeutics Company Profile
Turn Therapeutics, Inc. is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds. Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.
Featured Stories
- Five stocks we like better than Turn Therapeutics
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Turn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
